Osteoporosis is typically treated with orally administered drugs, which may take up to a year to have a noticeable effect. A ...

DNA hydrogels are biocompatible drug delivery systems for targeted therapeutic interventions. Conventional DNA hydrogels, formed with many DNA nanostructure units, lead to increased preparation costs ...

Allied Market Research published a report, titled, "Cell Culture Hydrogel Market By Type of Hydrogel (Natural Hydrogels, Synthetic Hydrogels, Hybrid Hydrogels), By Application (Cancer and Stem Cell ...

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a specialist in surgical and medical instruments with annual revenues of $13.55 million, has entered into a significant agreement with WellSpring ...

UroGen Pharma Ltd. is a biopharmaceutical company ... It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology.

Innovative Takumi-shaped DNA hydrogels exhibit prolonged retention and drug release, showcasing their potential as biocompatible delivery systems in medicine.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will particip ...

About UroGen Pharma Ltd. UroGen is a biotech company ... UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the ...